10-QPeriod: Q2 FY2008

CARDINAL HEALTH INC Quarterly Report for Q2 Ended Dec 31, 2007

Filed February 6, 2008For Securities:CAH

Summary

Cardinal Health, Inc. reported solid revenue growth for the quarter ended December 31, 2007, with a 7% increase year-over-year, driven by pharmaceutical price appreciation and volume increases, as well as contributions from recent acquisitions. While revenue climbed, the company faced increased selling, general, and administrative (SG&A) expenses and higher restructuring and acquisition integration charges, which tempered operating earnings growth to a more modest 1% increase. Net earnings saw a significant decrease of 56% compared to the prior year, largely influenced by a substantial one-time gain from discontinued operations in the prior year's comparable period. The company continued its share repurchase program, indicating confidence in its financial position and a commitment to returning value to shareholders. Investors should note the ongoing legal proceedings and the DEA matter, which present potential risks and uncertainties for future operations.

Key Highlights

  • 1Revenue increased by 7% to $23.3 billion for the quarter ended December 31, 2007, compared to the prior year, driven by pharmaceutical price appreciation and increased volume.
  • 2Operating earnings saw a modest increase of 1% to $519.2 million, despite higher SG&A expenses and special charges.
  • 3Net earnings decreased significantly by 56% to $324.7 million, primarily due to a large gain from discontinued operations in the prior year's period.
  • 4The company continued its share repurchase program, buying back approximately $350 million of its common stock during the quarter.
  • 5Significant litigation and regulatory matters are ongoing, including a DEA investigation related to controlled substance distribution and a voluntary recall of Alaris Pump modules.
  • 6The company adopted FIN No. 48, "Accounting for Uncertainty in Income Taxes," which resulted in a $139.3 million reduction in retained earnings.
  • 7Segment profit declined in the Pharmaceutical and Medical Supply Chain Services segments but grew substantially in Clinical Technologies and Services and Medical Products and Technologies.

Frequently Asked Questions

The substantial decrease in net earnings of 56% compared to the prior year was primarily due to a large one-time gain from discontinued operations recorded in the prior year's comparable period. While current quarter revenues increased, higher operating expenses and special charges impacted profitability.

Cardinal Health is facing several significant legal and regulatory matters, including a DEA investigation concerning the distribution of controlled substances, which has led to the suspension of licenses at three distribution centers. Additionally, the company has initiated a Class 1 voluntary recall for certain Alaris Pump modules due to potential over-infusion risks. While the company is actively addressing these issues, they represent potential risks to operations and financial performance.

Cardinal Health demonstrated a commitment to capital return through its ongoing share repurchase program, repurchasing approximately $350 million of its common stock during the quarter. The company also indicated adequate capital resources to fund anticipated expenditures and debt obligations, supported by its cash flow and available credit facilities.

The Pharmaceutical and Medical Supply Chain Services segments experienced a decline in segment profit, influenced by factors like increased customer discounting and contract repricing in pharmaceuticals, and rising SG&A expenses in medical services. In contrast, the Clinical Technologies and Services and Medical Products and Technologies segments showed robust growth in segment profit, driven by new products, acquisitions, and favorable product mix.